

FNDC5 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP8746b**Specification**

FNDC5 Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [Q8NAU1](#)**FNDC5 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 252995**Other Names**

Fibronectin type III domain-containing protein 5, Fibronectin type III repeat-containing protein 2, Irisin, FNDC5, FRCP2

Target/Specificity

The synthetic peptide sequence used to generate the antibody [BP8746b](#) was selected from the C-term region of human FNDC5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FNDC5 Antibody (C-term) Blocking Peptide - Protein Information**Name** FNDC5**Synonyms** FRCP2**Function**

[Irisin]: Mediates beneficial effects of muscular exercise. Induces browning of white adipose tissue by stimulating UCP1 expression, at least in part, via the nuclear receptor PPARA.

Cellular Location

[Fibronectin type III domain-containing protein 5]: Cell membrane; Single-pass membrane protein. Peroxisome membrane {ECO:0000250|UniProtKB:Q8K4Z2}; Single-pass membrane protein. Note=Imported into peroxisomes through the PEX5 receptor pathway. {ECO:0000250|UniProtKB:Q8K4Z2}

Tissue Location

Widely expressed, with highest levels in heart. Very low expression, if any, in colon, pancreas and spleen

FNDC5 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

FNDC5 Antibody (C-term) Blocking Peptide - Images

FNDC5 Antibody (C-term) Blocking Peptide - References

Teufel,A., et.al., Gene 297 (1-2), 79-83 (2002)